L
Lamia Mounedji-Boudiaf
Researcher at Sanofi S.A.
Publications - 3
Citations - 3299
Lamia Mounedji-Boudiaf is an academic researcher from Sanofi S.A.. The author has contributed to research in topics: Oxaliplatin & Colorectal cancer. The author has an hindex of 2, co-authored 3 publications receiving 3045 citations.
Papers
More filters
Journal ArticleDOI
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
Thierry André,Corrado Boni,Lamia Mounedji-Boudiaf,Matilde Navarro,Josep Tabernero,Tamas Hickish,C. Topham,Marta Zaninelli,Phillip Clingan,John Bridgewater,Isabelle Tabah-Fisch,Aimery de Gramont +11 more
TL;DR: Adding oxaliplatin to a regimen of fluorouracil and leucovorin improves the adjuvant treatment of colon cancer.
Journal Article
[Adjuvant treatment of colon cancer MOSAIC study's main results].
Thierry André,Christophe Tournigand,Emmanuel Achille,Nicole Tubiana-Mathieu,Gérard Lledo,Yves Raoul,Elisabeth Carola,M. Flesch,Thierry Muron,Arnaud Boutan-Laroze,Véronique Guérin Meyer,Catherine Boaziz,Michel Maigre,Gérard Ganem,Mireille Mousseau,Lamia Mounedji-Boudiaf,Aimery de Gramont +16 more
TL;DR: The Mosaic study confirmed the superior efficacy of the Folfox4 regimen compared to the standard treatment, the reduction in relapse risk being 24% and oxaliplatin was granted a marketing authorization for the indication adjuvant treatment of stage III colon cancer.
Journal Article
Traitement adjuvant du cancer du côlon : principaux résultats de l’étude MOSAIC*
Thierry André,Christophe Tournigand,Emmanuel Achille,Nicole Tubiana-Mathieu,Gérard Lledo,Yves Raoul,Elisabeth Carola,M. Flesch,Thierry Muron,Arnaud Boutan-Laroze,Véronique Guérin Meyer,Catherine Boaziz,Michel Maigre,Gérard Ganem,Mireille Mousseau,Lamia Mounedji-Boudiaf,Aimery de Gramont +16 more
TL;DR: Une nouvelle analyse effectuee avec un recul de 4 ans a confirme la superiorite du protocole Folfox4 sur le traitement standard ; la reduction du risque de rechute etait de 24 % (p = 0,0008).